Current Heart Failure Reports最新文献

筛选
英文 中文
Do Heart Failure Biomarkers Influence Heart Failure Treatment Response? 心力衰竭生物标志物影响心力衰竭治疗反应吗?
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-09-07 DOI: 10.1007/s11897-023-00625-x
Tiffany Yuen, Pishoy Gouda, Robert Margaryan, Justin Ezekowitz
{"title":"Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?","authors":"Tiffany Yuen,&nbsp;Pishoy Gouda,&nbsp;Robert Margaryan,&nbsp;Justin Ezekowitz","doi":"10.1007/s11897-023-00625-x","DOIUrl":"10.1007/s11897-023-00625-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Heart failure (HF) is one of the leading causes of cardiac morbidity and mortality around the world. Our evolving understanding of the cellular and molecular pathways of HF has led to the identification and evaluation of a growing number of HF biomarkers. Natriuretic peptides remain the best studied and understood HF biomarkers, with demonstrated clinical utility in the diagnosis and prognostication of HF. Less commonly understood is the utility of HF biomarkers for guiding and monitoring treatment response. In this review, we outline the current HF biomarker landscape and identify novel biomarkers that have potential to influence HF treatment response.</p><p><strong>Recent findings: </strong>An increasing number of biomarkers have been identified through the study of HF mechanisms. While these biomarkers hold promise, they have not yet been proven to be effective in guiding HF therapy. A more developed understanding of HF mechanisms has resulted in an increased number of available pharmacologic HF therapies. In the past, biomarkers have been useful for the diagnosis and prognostication of HF. Future evaluation on their use to guide pharmacologic therapy is ongoing, and there is promise that biomarker-guided therapy will allow clinicians to begin personalizing treatment for their HF patients.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"358-373"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association Between Intra-abdominal Pressure and Diuretic Response in Heart Failure. 心力衰竭患者腹腔内压力与利尿反应的关系。
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-07-29 DOI: 10.1007/s11897-023-00617-x
S Crespo-Aznarez, A Campos-Sáenz de Santamaría, M Sánchez-Marteles, V Garcés-Horna, C Josa-Laorden, I Giménez-López, J I Pérez-Calvo, J Rubio-Gracia
{"title":"The Association Between Intra-abdominal Pressure and Diuretic Response in Heart Failure.","authors":"S Crespo-Aznarez,&nbsp;A Campos-Sáenz de Santamaría,&nbsp;M Sánchez-Marteles,&nbsp;V Garcés-Horna,&nbsp;C Josa-Laorden,&nbsp;I Giménez-López,&nbsp;J I Pérez-Calvo,&nbsp;J Rubio-Gracia","doi":"10.1007/s11897-023-00617-x","DOIUrl":"10.1007/s11897-023-00617-x","url":null,"abstract":"<p><strong>Purpose of the review: </strong>An efficient diuretic response is vital during cardiac decompensation in heart failure (HF) patients. The increase in intra-abdominal pressure (IAP) could be one of the keys for understanding cardiorenal syndrome and guiding diuretic treatment during hospitalization. In this review, we analyze the relationship between IAP and diuretic response in HF patients.</p><p><strong>Recent findings: </strong>Increased IAP is associated with worsening renal function (WRF) in patients with advanced HF. Furthermore, the persistence of a rise in IAP after the first 72 h of intravenous diuretic treatment has been correlated with a worse diuretic response, a higher degree of congestion, and an impaired prognosis. The rise in IAP in HF patients has been associated with impaired renal function and a lower diuretic response. Nonetheless, more studies are needed to elucidate the actual role of IAP in congestive nephropathy and whether it may help guide diuretic therapy during acute decompensations.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"390-400"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telemedicine: an Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients. 远程医疗:新冠肺炎大流行给心力衰竭患者管理带来的有效且低成本的教训。
IF 3.4
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-09-04 DOI: 10.1007/s11897-023-00624-y
Paolo Severino, Silvia Prosperi, Andrea D'Amato, Claudia Cestiè, Vincenzo Myftari, Viviana Maestrini, Lucia Ilaria Birtolo, Domenico Filomena, Marco Valerio Mariani, Carlo Lavalle, Roberto Badagliacca, Massimo Mancone, Francesco Fedele, Carmine Dario Vizza
{"title":"Telemedicine: an Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients.","authors":"Paolo Severino, Silvia Prosperi, Andrea D'Amato, Claudia Cestiè, Vincenzo Myftari, Viviana Maestrini, Lucia Ilaria Birtolo, Domenico Filomena, Marco Valerio Mariani, Carlo Lavalle, Roberto Badagliacca, Massimo Mancone, Francesco Fedele, Carmine Dario Vizza","doi":"10.1007/s11897-023-00624-y","DOIUrl":"10.1007/s11897-023-00624-y","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this review is to explore the benefits and controversies that telemedicine (TM), applied to patients with heart failure (HF), can provide in terms of diagnosis, therapeutic management, and prognosis improvement. During the coronavirus disease 19 (COVID-19) outbreak, TM emerged as the most effective and feasible method available to ensure continuous care for chronic diseases. Among these, HF, characterized by high mortality, morbidity, and the need for frequent visits, may benefit of the TM role. HF patients are affected by frequent exacerbations undergoing a progressive prognosis impoverishment, strongly depending on the disease's management. A precise clinical handling is always required, with a constant optimization of the therapy, a continuous control of risk factors, and a sensitive attention to any change in symptoms, clinical signs, and laboratory tests. In this context, TM has shown to improve therapy adherence and HF: patients' self-care, impacting the prognosis even if specific results are controversial. Major evidence shows that TM may allow an adequate primary prevention, reducing the impact of the main cardiovascular risk factors. TM can also be useful for the secondary prevention, early detecting a likely HF exacerbation before it becomes clinically manifest, thereby lowering the need for hospitalization. Moreover, an optimal up-titration of the therapy and an increase in treatment adherence are feasible by using TM. However, some studies did not show unambiguous results, and uncertainties still remain.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"382-389"},"PeriodicalIF":3.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart Failure-Related Iron Deficiency Anemia Pathophysiology and Laboratory Diagnosis. 心力衰竭相关缺铁性贫血的病理生理学和实验室诊断。
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-08-26 DOI: 10.1007/s11897-023-00623-z
Silvio Nunes Augusto, Pieter Martens
{"title":"Heart Failure-Related Iron Deficiency Anemia Pathophysiology and Laboratory Diagnosis.","authors":"Silvio Nunes Augusto,&nbsp;Pieter Martens","doi":"10.1007/s11897-023-00623-z","DOIUrl":"10.1007/s11897-023-00623-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The goal of the current review is to give an overview regarding the pathophysiology of iron deficiency in heart failure and how different laboratory tests change in the setting of heart failure.</p><p><strong>Recent findings: </strong>Recent studies have questioned the current employed definition of iron deficiency in the field of heart failure, as patients with ferritin < 100ng/ml but TSAT > 20% have a better prognosis, no iron deficiency on bone marrow staining, and altered treatment response to ferric carboxymaltose. This review summarizes changes in iron parameters in the setting of heart failure and underscores the importance of a reduced bioavailability of iron documented by a low serum iron or TSAT, irrespective of the presence of anemia.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"374-381"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10072953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovering Distinct Phenotypical Clusters in Heart Failure Across the Ejection Fraction Spectrum: a Systematic Review. 在射血分数谱中发现心力衰竭的独特表型簇:一项系统综述。
IF 3.4
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-07-21 DOI: 10.1007/s11897-023-00615-z
Claartje Meijs, M Louis Handoko, Gianluigi Savarese, Robin W M Vernooij, Ilonca Vaartjes, Amitava Banerjee, Stefan Koudstaal, Jasper J Brugts, Folkert W Asselbergs, Alicia Uijl
{"title":"Discovering Distinct Phenotypical Clusters in Heart Failure Across the Ejection Fraction Spectrum: a Systematic Review.","authors":"Claartje Meijs, M Louis Handoko, Gianluigi Savarese, Robin W M Vernooij, Ilonca Vaartjes, Amitava Banerjee, Stefan Koudstaal, Jasper J Brugts, Folkert W Asselbergs, Alicia Uijl","doi":"10.1007/s11897-023-00615-z","DOIUrl":"10.1007/s11897-023-00615-z","url":null,"abstract":"<p><strong>Review purpose: </strong>This systematic review aims to summarise clustering studies in heart failure (HF) and guide future clinical trial design and implementation in routine clinical practice.</p><p><strong>Findings: </strong>34 studies were identified (n = 19 in HF with preserved ejection fraction (HFpEF)). There was significant heterogeneity invariables and techniques used. However, 149/165 described clusters could be assigned to one of nine phenotypes: 1) young, low comorbidity burden; 2) metabolic; 3) cardio-renal; 4) atrial fibrillation (AF); 5) elderly female AF; 6) hypertensive-comorbidity; 7) ischaemic-male; 8) valvular disease; and 9) devices. There was room for improvement on important methodological topics for all clustering studies such as external validation and transparency of the modelling process. The large overlap between the phenotypes of the clustering studies shows that clustering is a robust approach for discovering clinically distinct phenotypes. However, future studies should invest in a phenotype model that can be implemented in routine clinical practice and future clinical trial design. HF = heart failure, EF = ejection fraction, HFpEF = heart failure with preserved ejection fraction, HFrEF = heart failure with reduced ejection fraction, CKD = chronic kidney disease, AF = atrial fibrillation, IHD = ischaemic heart disease, CAD = coronary artery disease, ICD = implantable cardioverter-defibrillator, CRT = cardiac resynchronization therapy, NT-proBNP = N-terminal pro b-type natriuretic peptide, BMI = Body Mass Index, COPD = Chronic obstructive pulmonary disease.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"333-349"},"PeriodicalIF":3.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9846360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices. 成人先天性心脏病心力衰竭的新治疗策略:药物和器械。
Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-08-16 DOI: 10.1007/s11897-023-00621-1
Sumeet Vaikunth, Swethika Sundaravel, Joshua Saef, Juan Ortega-Legaspi
{"title":"Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices.","authors":"Sumeet Vaikunth,&nbsp;Swethika Sundaravel,&nbsp;Joshua Saef,&nbsp;Juan Ortega-Legaspi","doi":"10.1007/s11897-023-00621-1","DOIUrl":"10.1007/s11897-023-00621-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>This paper reviews the latest literature on the growing field of heart failure in the adult congenital heart disease population.</p><p><strong>Recent findings: </strong>After highlighting the increasing prevalence and a few of the unique potential causes, including the concept of early senescence, this review begins with novel medical management strategies such as the angiotensin II receptor blocker and neprilysin inhibitors and sodium glucose cotransporter-2 inhibitors. Then, it addresses the latest applications of percutaneous techniques like implantable hemodynamic monitoring, transcatheter pulmonary and aortic valve replacement, and mitral clips. Cardiac resynchronization therapy and novel lymphatic system imaging and intervention are then described. Finally, the use of mechanical support devices, temporary and durable, is discussed as well as heart and combined heart and liver transplantation. There have been recent exciting advances in the strategies used to manage adult congenital heart disease patients with heart failure. As this population continues to grow, it is likely we will see further rapid evolution in this field.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"401-416"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10009219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. 电子健康记录嵌入式策略改善心力衰竭患者的护理。
Current Heart Failure Reports Pub Date : 2023-08-01 DOI: 10.1007/s11897-023-00614-0
Michael A Fuery, Bashar Kadhim, Marc D Samsky, James V Freeman, Katherine Clark, Nihar R Desai, Francis P Wilson, Treeny Ahmed, Tariq Ahmad
{"title":"Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure.","authors":"Michael A Fuery,&nbsp;Bashar Kadhim,&nbsp;Marc D Samsky,&nbsp;James V Freeman,&nbsp;Katherine Clark,&nbsp;Nihar R Desai,&nbsp;Francis P Wilson,&nbsp;Treeny Ahmed,&nbsp;Tariq Ahmad","doi":"10.1007/s11897-023-00614-0","DOIUrl":"https://doi.org/10.1007/s11897-023-00614-0","url":null,"abstract":"<p><strong>Purpose: </strong>A majority of clinical decisions use the electronic health record (EHR) and there is an unmet need to use its capability to help providers to make evidence-based decisions that improve care for heart failure patients. These electronic nudges are rooted in the human psychology of decision-making and often target specific cognitive biases. This review outlines the development of novel EHR nudges and specific lessons learned from each experience to inform the development of future interventions.</p><p><strong>Recent findings: </strong>There have been several randomized clinical trials examining the impact of EHR alerts on quality of care for heart failure patients. These interventions have targeted both clinicians and patients. There are features of each trial that inform best practices and future directions for EHR nudges. Recent clinical trials have demonstrated that some EHR alerts can improve care for heart failure patients. These trials utilized default options, involved clinicians in the alert design process, provided actionable recommendations, and aimed to minimize disruptions to typical workflow. Alerts aimed at improving care should be examined in a randomized fashion in order to evaluate their impact on clinician satisfaction and patient care.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 4","pages":"280-286"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10228842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials? 心力衰竭缺铁的病理生理学和治疗机会:是否需要进一步的试验?
Current Heart Failure Reports Pub Date : 2023-08-01 Epub Date: 2023-07-10 DOI: 10.1007/s11897-023-00611-3
Michał Tkaczyszyn, Marat Fudim, Piotr Ponikowski, Jan Biegus
{"title":"Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?","authors":"Michał Tkaczyszyn,&nbsp;Marat Fudim,&nbsp;Piotr Ponikowski,&nbsp;Jan Biegus","doi":"10.1007/s11897-023-00611-3","DOIUrl":"10.1007/s11897-023-00611-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Iron deficiency (ID) complicates heart failure (HF) at different stages of the natural history of the disease; however, this frequent comorbidity is still not comprehensively understood and investigated in terms of pathophysiology. Intravenous iron therapy with ferric carboxymaltose (FCM) should be considered to improve the quality of life, exercise capacity, and symptoms in stable HF with ID, as well as to reduce HF hospitalizations in iron-deficient patients stabilized after an episode of acute HF. The therapy with intravenous iron, however, continues to generate important clinical questions for cardiologists.</p><p><strong>Recent findings: </strong>In the current paper, we discuss the class effect concept for intravenous iron formulations beyond FCM, based on the experiences of nephrologists who administer different intravenous iron formulations in advanced chronic kidney disease complicated with ID and anemia. Furthermore, we discuss the neutral effects of oral iron therapy in patients with HF, because there are still some reasons to further explore this route of supplementation. The different definitions of ID applied in HF studies and new doubts regarding possible interactions of intravenous iron with sodium-glucose co-transporter type 2 inhibitors are also emphasized. The experiences of other medical specializations may provide new information on how to optimally replenish iron in patients with HF and ID.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 4","pages":"300-307"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10585583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. 肺动脉高压右心室功能障碍的医学处理。
Current Heart Failure Reports Pub Date : 2023-08-01 DOI: 10.1007/s11897-023-00612-2
Annalisa Caputo, Silvia Papa, Giovanna Manzi, Domenico Laviola, Tommaso Recchioni, Paolo Severino, Carlo Lavalle, Viviana Maestrini, Massimo Mancone, Roberto Badagliacca, Carmine Dario Vizza
{"title":"Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.","authors":"Annalisa Caputo,&nbsp;Silvia Papa,&nbsp;Giovanna Manzi,&nbsp;Domenico Laviola,&nbsp;Tommaso Recchioni,&nbsp;Paolo Severino,&nbsp;Carlo Lavalle,&nbsp;Viviana Maestrini,&nbsp;Massimo Mancone,&nbsp;Roberto Badagliacca,&nbsp;Carmine Dario Vizza","doi":"10.1007/s11897-023-00612-2","DOIUrl":"https://doi.org/10.1007/s11897-023-00612-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to overview the most relevant and recent knowledge regarding medical management in pulmonary arterial hypertension (PAH).</p><p><strong>Recent findings: </strong>Evidence has shown that PAH patients' quality of life and prognosis depend on the capability of the RV to adapt to increased afterload and to fully recover in response to substantially reduced pulmonary vascular resistance obtained with medical therapy. Data from recent clinical studies show that more aggressive treatment strategies, especially in higher risk categories, determine larger afterload reductions, consequentially increasing the probability of achieving right heart reverse remodeling, therefore improving the patients' survival and quality of life. Remarkable progress has been observed over the past decades in the medical treatment of PAH, related to the development of drugs that target multiple biological pathways, strategies for earlier and more aggressive treatment interventions. New hopes for treatment of patients who are unable to achieve low-risk status have been derived from the phase 2 trial PULSAR and the phase 3 trial STELLAR, which show improvement in the hemodynamic status of patients treated with sotatercept on top of background therapy. Promising results are expected from several ongoing clinical trials targeting new pathways involved in the pathophysiology of PAH.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 4","pages":"263-270"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10240797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-Related Differences in Heart Failure Diagnosis. 心力衰竭诊断的性别差异
Current Heart Failure Reports Pub Date : 2023-08-01 DOI: 10.1007/s11897-023-00609-x
Daniela Maidana, Clara Bonanad, Carolina Ortiz-Cortés, Andrea Arroyo-Álvarez, Guillermo Barreres-Martín, Carles Muñoz-Alfonso, Eva Maicas-Alcaine, Cristina García-Pérez, Andrea Aparici-Redal, Victòria Freitas-Durks, Alberto Esteban-Fernández
{"title":"Sex-Related Differences in Heart Failure Diagnosis.","authors":"Daniela Maidana,&nbsp;Clara Bonanad,&nbsp;Carolina Ortiz-Cortés,&nbsp;Andrea Arroyo-Álvarez,&nbsp;Guillermo Barreres-Martín,&nbsp;Carles Muñoz-Alfonso,&nbsp;Eva Maicas-Alcaine,&nbsp;Cristina García-Pérez,&nbsp;Andrea Aparici-Redal,&nbsp;Victòria Freitas-Durks,&nbsp;Alberto Esteban-Fernández","doi":"10.1007/s11897-023-00609-x","DOIUrl":"https://doi.org/10.1007/s11897-023-00609-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>The literature on the importance of sex in heart failure diagnosis is scarce. This review aims to summarize current knowledge on sex differences regarding the diagnosis of heart failure.</p><p><strong>Recent findings: </strong>Comorbidities are frequent in patients with heart failure, and their prevalence differs between sexes; some differences in symptomatology and diagnostic imaging techniques were also found. Biomarkers also usually show differences between sexes but are not significant enough to establish sex-specific ranges. This article outlines current information related to sex differences in HF diagnosis. Research in this field remains to be done. Maintaining a high diagnostic suspicion, actively searching for the disease, and considering the sex is relevant for early diagnosis and better prognosis. In addition, more studies with equal representation are needed.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 4","pages":"254-262"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10602237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信